FDAapproval83% confidence
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Bayer.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Gynecology · Endometrial Hyperplasia
- Sub-indication
- General
Related signal: Bayer's Mirena Investigated for Nonatypical Endometrial Hyperplasia Treatment